ATE419006T1 - Multivalenter dengue-virus impfstoff - Google Patents

Multivalenter dengue-virus impfstoff

Info

Publication number
ATE419006T1
ATE419006T1 AT00919748T AT00919748T ATE419006T1 AT E419006 T1 ATE419006 T1 AT E419006T1 AT 00919748 T AT00919748 T AT 00919748T AT 00919748 T AT00919748 T AT 00919748T AT E419006 T1 ATE419006 T1 AT E419006T1
Authority
AT
Austria
Prior art keywords
dengue
virus
dengue virus
virus vaccine
attenuated
Prior art date
Application number
AT00919748T
Other languages
German (de)
English (en)
Inventor
Kenneth Eckels
Joseph Putnak
Doria Dubois
Bruce Innis
Charles Hoke
Sun Wellington
Kanesa-Thasan Niranjan
Original Assignee
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army filed Critical Us Army
Application granted granted Critical
Publication of ATE419006T1 publication Critical patent/ATE419006T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00919748T 1999-03-26 2000-03-24 Multivalenter dengue-virus impfstoff ATE419006T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12631399P 1999-03-26 1999-03-26
US18172400P 2000-02-11 2000-02-11

Publications (1)

Publication Number Publication Date
ATE419006T1 true ATE419006T1 (de) 2009-01-15

Family

ID=26824502

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00919748T ATE419006T1 (de) 1999-03-26 2000-03-24 Multivalenter dengue-virus impfstoff

Country Status (12)

Country Link
US (2) US6638514B1 (https=)
EP (1) EP1165127B1 (https=)
JP (1) JP2002540168A (https=)
KR (1) KR100721745B1 (https=)
CN (1) CN1191092C (https=)
AT (1) ATE419006T1 (https=)
AU (1) AU779280B2 (https=)
CA (1) CA2368674A1 (https=)
DE (1) DE60041250D1 (https=)
ES (1) ES2322327T3 (https=)
MX (1) MXPA01009683A (https=)
WO (1) WO2000057907A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン
DK2290109T3 (da) 2001-05-22 2014-11-10 Us Gov Health & Human Serv Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
BRPI0613287A2 (pt) 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CL2008003202A1 (es) * 2007-10-29 2009-11-27 Boehringer Ingelheim Vetmedica Inc Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.
EP2376923A4 (en) * 2008-12-22 2012-08-15 Children S Res Inst METHOD FOR DETECTING SEPSIS
AR075437A1 (es) 2009-02-17 2011-03-30 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamento
NZ597000A (en) * 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
ES2436317T3 (es) 2010-05-07 2013-12-30 Deutsches Krebsforschungszentrum Parvovirus de roedor modificado capaz de propagarse y difundirse en gliomas humanos
BR112015031226A2 (pt) * 2013-06-21 2017-08-29 Merck Sharp & Dohme Composição de vacina, e, uso da composição de vacina
EP3236997B1 (en) 2014-12-22 2024-05-29 Merck Sharp & Dohme LLC Dengue virus vaccine compositions and methods of use thereof
CN107921063A (zh) 2015-07-02 2018-04-17 普莱瓦克斯免疫肿瘤学公司 用于采用登革病毒与树突细胞的联合疗法的组合物及方法
CN108291205A (zh) 2015-09-26 2018-07-17 普莱瓦克斯免疫肿瘤学公司 用于产生树突细胞的组合物和方法
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
CN105801674B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p7及其应用
CN105777877B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p4及其应用
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
WO2018165373A1 (en) * 2017-03-08 2018-09-13 University Of Georgia Research Foundation, Inc. Methods and compositions related to increased viral production
KR20200023375A (ko) * 2017-06-15 2020-03-04 프라임벡스 이뮤노-온콜로지, 인크. 뎅기 바이러스 및 수지상 세포를 이용하는 암 요법을 위한 조성물 및 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06181792A (ja) * 1992-06-05 1994-07-05 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法、およびそれに用いる組み換えウイルス
EP0705109B2 (en) 1993-05-25 2004-01-02 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus
AU6093296A (en) * 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
EP0948256A4 (en) * 1996-10-28 2007-10-24 Univ Washington INDUCTION OF VIRAL MUTATIONS BY INTRODUCTION TO ERROR-CODED RIBONUCLEOSIDE ANALOGUES IN VIRAL RNA
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン

Also Published As

Publication number Publication date
WO2000057907A2 (en) 2000-10-05
WO2000057907A9 (en) 2002-04-11
US6638514B1 (en) 2003-10-28
CN1351502A (zh) 2002-05-29
KR100721745B1 (ko) 2007-05-25
KR20020008136A (ko) 2002-01-29
DE60041250D1 (de) 2009-02-12
ES2322327T3 (es) 2009-06-19
CA2368674A1 (en) 2000-10-05
EP1165127A2 (en) 2002-01-02
AU779280B2 (en) 2005-01-13
MXPA01009683A (es) 2003-06-24
AU4038200A (en) 2000-10-16
WO2000057907A3 (en) 2001-04-12
CN1191092C (zh) 2005-03-02
US7217418B2 (en) 2007-05-15
JP2002540168A (ja) 2002-11-26
EP1165127B1 (en) 2008-12-31
US20070087015A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
DE60041250D1 (de) Multivalenter dengue-virus impfstoff
Tuiskunen Bäck et al. Dengue viruses–an overview
MY192806A (en) Compositions and methods of vaccination against dengue virus in children and young adults
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
ZA200900935B (en) Hepatitis C virus inhibitors
DE60334205D1 (en) Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
PE20020474A1 (es) Compuestos peptidomimeticos como inhibidores de la serina proteasa ns3 del virus de hepatitis c
NO20044897L (no) Hepatitt C virus inhibitorer
MY180698A (en) Immunization protocol against the 4 dengue serotypes
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
MY169275A (en) Method of immunization against the four serotypes of dengue
Li et al. Inhibition of Japanese encephalitis virus entry into the cells by the envelope glycoprotein domain III (EDIII) and the loop3 peptide derived from EDIII
ATE521627T1 (de) Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins
JP2002540168A5 (https=)
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
JP2016504315A5 (https=)
WO2000057908A3 (en) Attenuated dengue-1 virus vaccine
WO2000057904A3 (en) Attenuated dengue-3 virus vaccine
Roberts et al. New opportunities for control of dengue virus
ATE456953T1 (de) Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga
Briggs et al. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination
Simmons et al. Advances in the development of vaccines for dengue fever

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties